Large Animal/Histomorphometry

动物/组织形态计量学核心的目标是为研究人员提供项目资助 (PPG)为设计和执行涉及动物的研究提供科学、技术和财政支持， 心脏组织的组织形态测定评估。我们最先进的设施容纳并包含所有 执行实验和分析冠状动脉病变犬标本所需的动物和设备 微栓塞诱导的心力衰竭（HF）以及快速起搏诱导的HF犬。来 在过去的23年里，我们已经开发出了一种理想的慢性HF犬模型， 适用于PPG中概述的研究。该模型中的心力衰竭是由多个连续的 微球冠状动脉内栓塞导致存活心肌丧失。该模型体现了 人类HF的许多（如果不是全部）后遗症包括严重的收缩和舒张LV功能障碍，LV 扩张和代偿性肥大，LV充盈压增加，全身血管扩张和代偿性肥大， 阻力，心输出量减少，重要的是，线粒体和特征性 LV功能进行性恶化。核心将执行以下目标：1）协调 参与冠状动脉微栓塞诱导HF研究的犬的采集、圈养和准备， 2)执行涉及冠状动脉微栓塞诱导HF的药理学方案，即假设 负责项目2的治疗方案，3）协调犬和心脏组织的分配 来源于冠状动脉微栓塞诱导的HF实验和4）进行组织学分析， 来自冠状动脉微栓塞诱导HF和小鼠研究的组织样本（项目1、2和 4)以及快速起搏诱导HF的犬，其特异于PPG的项目3。服务 PPG研究者将由核心负责人（Dr. H.N. Sabbah），核心公司- 组长（V.G.博士）Sharov博士）、1名助理调查员（M. Wang）和1名执业兽医 技术专家（Annette Hazel女士）。设施兽医（格雷戈里·海西博士）是一个机构资源 并将免费提供所有必要和必需的兽医支持。

The objective of the Animal/Histomorphometry core is to provide investigators of the program project grant (PPG) scientific, technical and financial support for the design and execution of studies involving animals and histomorphometric assessment of cardiac tissue. Our state-of-the art facility houses and contains all the animals and equipment necessary to execute experiments and analyze specimens from dogs with coronary microembolization-induced heart failure (HF) as well as from dogs with rapid pacing-induced HF. Over the past 23 years, we have developed and fully characterized a canine model of chronic HF which is ideally suited for the studies outlined in the PPG. Heart failure in this model is produced by multiple sequential intracoronary embolizations with microspheres that lead to loss of viable myocardium. The model manifests many, if not all of the sequelae of HF in humans including profound systolic and diastolic LV dysfunction, LV dilation and compensatory hypertrophy, increased LV filling pressures, increased systemic vascular resistance, decreased cardiac output and, importantly, abnormalities of mitochondria and characteristic progressive worsening of LV function. The Core will the perform the following aims: 1) coordinate the acquisition, housing and preparation of dogs involved in the coronary microembolization-induced HF studies, 2) execute pharmacologic protocols involving coronary microembolization-induced HF i.e. assume responsibility for treatment regimens for project 2, 3) coordinate distribution of dogs and cardiac tissues derived from coronary microembolization-induced HF experiments and 4) perform histological analysis of tissue samples derived from coronary-microembolization induced HF and mouse studies (Projects 1, 2 and 4) as well as from dogs with rapid-pacing-induced HF that are specific to project 3 of the PPG. Services to PPG investigators will be provided by a team consisting of the Core Leader (Dr. H.N. Sabbah), the Core Co- Leader (Dr. V.G. Sharov), 1 Assistant Staff Investigator (Dr M. Wang) and 1 Licensed Veterinary Technologists (Ms. Annette Hazel). The facility veterinarian (Dr. Gregory Heisey) is an institutional resource and will provide all the necessary and required veterinary support without charge.